C4 Therapeutics Inc (CCCC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, C4 Therapeutics Inc (CCCC) has a cash flow conversion efficiency ratio of -0.128x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-29.94 Million) by net assets ($234.25 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see C4 Therapeutics Inc stock valuation for the company's overall valuation and market capitalisation.
C4 Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how C4 Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
C4 Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of C4 Therapeutics Inc ranked by their cash flow conversion efficiency. See C4 Therapeutics Inc cash flow to debt ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ARS Pharmaceuticals, Inc
NASDAQ:SPRY
|
-0.381x |
|
IGG Inc
F:I91
|
-0.006x |
|
Focus Hotmelt Co. Ltd. A
SHE:301283
|
N/A |
|
Yunnan Yuntou Ecology and Environment Technology Co Ltd
SHE:002200
|
-0.032x |
|
Volatus Aerospace Inc
V:FLT
|
-0.152x |
|
Hunan Sokan New Materials Co. Ltd. A
SHG:688157
|
N/A |
|
SNT Motiv Co Ltd
KO:064960
|
0.028x |
|
Prime Energy PE Ltd
TA:PRIM
|
-0.084x |
Annual Cash Flow Conversion Efficiency for C4 Therapeutics Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of C4 Therapeutics Inc from 2018 to 2025. View current stock price of C4 Therapeutics Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $256.59 Million | $-98.69 Million | -0.385x | -27.50% |
| 2024-12-31 | $215.99 Million | $-65.16 Million | -0.302x | +30.51% |
| 2023-12-31 | $246.11 Million | $-106.84 Million | -0.434x | -18.52% |
| 2022-12-31 | $289.23 Million | $-105.94 Million | -0.366x | -64.09% |
| 2021-12-31 | $389.61 Million | $-86.97 Million | -0.223x | +6.80% |
| 2020-12-31 | $280.79 Million | $-67.25 Million | -0.239x | +51.78% |
| 2019-12-31 | $-111.96 Million | $55.61 Million | -0.497x | -333.28% |
| 2018-12-31 | $-79.75 Million | $-16.98 Million | 0.213x | -- |
About C4 Therapeutics Inc
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology p… Read more